Auger Molecular Therapy (AMT) is designed for tumors on or close to the body surface. The current indication approved by US FDA for clinical trial is malignant wound
Malignant Fungating Wound
Malignant Fungating Wound (MFW) occurs in around 5-10% of cancer patients worldwide.
MFW is originated from invasion of solid neoplasm to skin surface causing open lesion.
Usually occurs in late stage or recurrence cancer patients.
No treatment regimen is designed specifically to combat against MFW.
Palliative treatment is the only option with goals of symptom control and improving quality of life for patients.
Ocular melanoma is a typically malignant eye cancer caused by enriched blood flow and high metastasis ability.
Malignant eye cancer patients end up with “enucleation”, which causes extremely low quality of life.
Traditional radiation therapy leads to enormous side effects to retina and optic nerves. A low electron energy of 33keV of AMT X-ray has an average penetration of 1.6cm without extra radio-harm to the tissue nearby. This could be a novel cancer radiotherapy.
